论文部分内容阅读
十年前,人们开始认识到因子Ⅷ和Ⅸ浓制剂有传播非甲非乙型(NANB)肝炎的危险。需要用大量混合血浆(在英国的生产厂,混合血浆达7000人份,某些商品制剂生产所用混合血浆的人份甚至更多)作原料生产因于Ⅷ,给从未用过因子Ⅷ的病人使用未经加热处理的因子Ⅷ,感染率接近100%。急性肝炎症状通常轻微;暴发型肝炎仅限于原有慢性肝病(通常是非病毒性的)的病人。然而现在才清楚,实际上还存在着发生慢性后遗症的危险性(如慢性活动性肝炎和肝硬化)。定期用因
Ten years ago, people began to recognize the risk of Factor VIII and IX concentrates in transmitting non-A, non-B hepatitis. Need to use a large number of mixed plasma (in the UK production plant, the mixed plasma of up to 7,000 people, some of the commercial production of mixed plasma or even more people) as raw material production due to Ⅷ, to never used factor Ⅷ patients Using factor Ⅷ without heat treatment, the infection rate is close to 100%. Acute hepatitis symptoms are usually mild; fulminant hepatitis is limited to patients with chronic (usually non-viral) liver disease. However, it is now clear that there is in fact the danger of developing chronic sequelae (such as chronic active hepatitis and cirrhosis). Regular use